ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

リソフィリン

Lisofylline

HCID 501254
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
100324-81-0
標準SMILES
C[C@@H](O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
InChIKey
NSMXQKNUPPXBRG-SECBINFHSA-N
分子式
C13H20N4O3
平均分子量
280.32 g/mol
単同位体質量
280.15354051

概要

(R)-lisofylline is a 1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione that has (R)-configuration. A synthetic small molecule which was under development for the treatment of type 1 diabetes mellitus. It has a role as an immunomodulator and an anti-inflammatory agent. It is an enantiomer of a (S)-lisofylline.

名称と識別子

優先名称
Lisofylline
IUPAC
1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione
現地名
リソフィリン
英語名
1-(5-hydroxyhexyl)-3,7-dimethyl-purine-2,6-dione
分子式
C13H20N4O3
分子量
280.32

名称と別名

(R)-LisofyllineLISOFYLLINE100324-81-0ProTecLisophyllineCT-1501RlisofilinaCT 1501R1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dioneLisofylline, (r)-lisofyllinumCT1501R
名称をさらに表示
リソフィリン(R)-Lisofylline, 10 mM in DMSO1-(5-hydroxyhexyl)-3,7-dimethyl-purine-2,6-dione3,7-Dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-diMethyl-(R)-1-(5-Hydroxyhexyl)-3,7-dimethyl-1H-purine-2,6(3H,7H)-dione
(R)-Lisophylline1-[(R)-5-hydroxyhexyl]theobromine1-(5R-Hydroxyhexyl)-3,7-dimethylxanthineDTXSID7058709CHEBI:143527L1F2Q2X9561-((R)-5-Hydroxyhexyl)theobromine1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

データベース識別子

CAS
100324-81-0
PubChem CID
501254
DTXSID
DTXSID7058709
ChEMBL
CHEMBL1411

物性

構造計算による物性

XLogP
0.7
極性表面積
78.7 Ų
水素結合供与体数
1
水素結合受容体数
4
回転可能結合数
5
重原子数
20
形式電荷
0
複雑度
390

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Metabolite of Pentoxifylline

物理化学的性質

融点
105 · 105-107°C
比旋光度
20 · D20 -5.6° (c = 6.7 in ethanol)
沸点
511.2 · 511.2±56.0 °C(Predicted)
比重(密度)
1.32 · 1.32±0.1 g/cm3(Predicted)
貯蔵温度
-20 °C · Hygroscopic, -20°C Freezer, Under Inert Atmosphere
溶解性
クロロホルム、メタノール
外見
個体
酸解離定数(Pka)
15.22 · 15.22±0.20(Predicted)
色
ホワイトからオフホワイト
安定性
吸湿性

化学的性質

化学的特性White Solid

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

安全データ

危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H302

化学と産業

薬理情報

Metabolism/MetabolitesLisofylline has known human metabolites that include pentoxifylline and lisofylline 4,5-diol.
MeSH Pharmacological Classification · 4 件

Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.

Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells.

関連反応

2 件
反応記録を作成
HRID 348782 の反応式
HRID 348782反応物として
HRID 553329 の反応式
HRID 553329反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
ChEBI
CHEBI:143527
UNII
L1F2Q2X956
Nikkaji
J731.039K